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the Ratios of monounsaturated 
to saturated phosphatidylcholines 
in lung adenocarcinoma 
microenvironment analyzed by 
Liquid Chromatography-Mass 
spectrometry and imaging Mass 
spectrometry
Yusuke Muranishi1, toshihiko sato2, shinji Ito3, Junko satoh3, Akihiko Yoshizawa4, 
shigeyuki tamari5, Yuichiro Ueda2,5,6, Yojiro Yutaka5,6, toshi Menju5, tatsuo Nakamura6 & 
Hiroshi Date5
Adenocarcinoma is the most common type of lung cancer, and can be classified into various histologic 
subtypes. However, little is known about the subtype-dependent variations in lipid metabolism 
processes. We performed dual lipidomic analyses using liquid chromatography–mass spectrometry 
(LC-Ms) and matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMs) to 
identify possible biomarkers to distinguish adenocarcinoma specimens from normal lung specimens, 
and to determine if there are any differences in lipid metabolism among the histologic subtypes 
(lepidic, acinar, papillary, micropapillary, solid, and mucinous). LC-Ms was used to characterize 
the lipid profiles of lung adenocarcinoma and normal lung tissue, and MALDI-IMS analysis was 
performed to confirm the results with information on lipid localization within the lung. LC-MS analysis 
found significant differences in the relative abundances of phosphatidylcholine (PC)(16:0/16:0) 
(P = 0.0432) and sphingomyelin (SM)(42:2) (P < 0.0001) between adenocarcinoma and normal lung 
specimens. The ratios of PC(16:0/16:1)/PC(16:0/16:0), PC(16:0/18:1)/PC(16:0/16:0), and PC(16:0/18:1)/
PC(16:0/18:0) were significantly higher in adenocarcinoma specimens (P = 0.02221, P = 0.0004, and 
P = 0.0215, respectively). MALDI-IMS analysis confirmed that these ratios were significantly higher in 
adenocarcinoma regions of the lung. The ratio of PC(16:0–18:1)/PC(16:0–18:0) was significantly lower in 
solid subtypes than in other subtypes (P = 0.0028). The monounsaturated/saturated PC ratios may have 
applications in adenocarcinoma diagnoses and subtyping.
Lung cancer is a major cause of cancer-related death throughout the world, and is often associated with a poor 
prognosis. Non-small-cell lung carcinomas account for approximately 85% of all lung cancers, and include ade-
nocarcinomas, squamous cell carcinomas, and large-cell carcinomas1. Among these, adenocarcinomas represent 
the most common histologic variant of lung cancer2.
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In 2011, the International Association for the Study of Lung Cancer, the American Thoracic Society, and the 
European Respiratory Society collaboratively developed a classification scheme to standardize the diagnostic cri-
teria for lung adenocarcinomas3. In this system, lung adenocarcinomas are histologically classified into atypical 
adenomatous hyperplasia, adenocarcinomas in situ, minimally invasive adenocarcinomas, and invasive adeno-
carcinomas. Invasive adenocarcinomas are further divided into lepidic predominant, papillary predominant, aci-
nar predominant, micropapillary predominant, solid predominant, invasive mucinous, and colloid/fetal/enteric 
predominant subtypes (Supplementary Table 1). These classifications have demonstrated good correlations with 
pathological malignancy and patient prognoses4.
The metabolic processes of cancer have been extensively investigated5. For example, recent studies have 
reported on the relationship between tumour progression and lipid metabolism6,7. In addition, the expression of 
monounsaturated lipids has been found to be significantly higher than that of saturated lipids in various forms 
of cancer, including lung cancer8–11. Several types of phospholipids have therefore been proposed as candidate 
biomarkers for lung cancer12–16.
However, no reports in the existing literature have described lipid metabolism in lung adenocarcinoma 
according to the different histologic subtypes. We hypothesized that the different subtypes would have dissimilar 
lipid metabolic processes due to their variations in prognoses, pathological malignancy, and pathological find-
ings4. The aim of this study was to identify a distinct biomarker that can be used to differentiate adenocarcinoma 
from normal lung tissue. We also investigated if the different adenocarcinoma subtypes have distinctive phos-
pholipid profiles.
In this study, we conducted a comprehensive investigation of the lipid profiles of lung adenocarcinoma and 
normal lung specimens using liquid chromatography–MS (LC-MS). These results were revaluated and confirmed 
using matrix-assisted laser desorption/ionization imaging MS (MALDI-IMS) supplemented with information on 
the lung localization of each lipid.
Results
patient characteristics. The clinicopathological features of the patients are shown in Table 1. Samples from 
Patients 1 to 6 were subjected to both LC-MS and MALDI-IMS analyses. The majority of patients presented with 
Stage I tumours. Solid tumours (observed in 8 cases) were the most common of all subtypes. This was followed 
by papillary (7 cases), invasive mucinous (3 cases), acinar (3 cases), micropapillary (2 cases), and lepidic (2 cases) 
subtypes.
LC-Ms analysis results. The S-plot of the orthogonal projections to latent structures discriminant analysis 
(OPLS-DA) revealed abundant ions at m/z 782.57 and m/z 760.58 in the adenocarcinoma specimens, whereas 
ions at m/z 734.57 and m/z 813.68 were more abundant in the normal lung specimens (Fig. 1A) We show the 
scores plot for OPLS-DA (Fig. 1B). Progenesis QI software predicted that these ions are derived from lipid species 
that are generally abundant in lung specimens12,14,17,18. We show the top four variable importance in projection 
(VIP) scores of the OPLS-DA and the corresponding m/z (Table 2). The scores were calculated by EZinfo soft-
ware (Waters). The highest VIP score was 23.9762 (for the ion with m/z of 734.568 and retention time 8.23 min), 
followed by 19.7024 (m/z of 813.68 and retention time 13.51 min), 15.1571 (m/z of 760.58 and retention time 
8.51 min) and 14.1025 (m/z of 782.56 and retention time 6.66 min). We further examined these lipid species 
through authentic MS/MS spectral analyses using the same LC-MS system. As summarized in Supplementary 
Table 2 and Supplementary Fig. 1A–F, the Progenesis QI predictions were confirmed by the authentic MS/MS 
spectral analyses. By matching the retention times and MS/MS fragmentation patterns with those of standard 
compounds, the ions at m/z 734.57 (Supplementary Fig. 1A) and m/z 760.58 (Supplementary Fig. 1B) were iden-
tified to be the protonated ions of PC (16:0/16:0) and PC (16:0/18:1), respectively. The retention time of ions 
at m/z 782.57 was close to that of other PCs, and the MS/MS fragmentation pattern matched that of PC (36:4) 
(Supplementary Fig. 1C). The retention time of ions at m/z 813.68 was close to the elution range for sphingo-
myelin (SM) under the same LC conditions, and its MS/MS fragmentation pattern matched that of SM (42:2) 
(Supplementary Fig. 1D). We also examined other ions (m/z 762.60 and m/z 732.55) that were abundant in the 
lung sample. By matching the retention times and MS/MS fragmentation patterns with those of standard com-
pounds (Supplementary Fig. 1E), the ions at m/z 762.60 were identified to be PC (16:0/18:0). The retention time 
of ions at m/z 732.55 was close to that of other PCs, and the MS/MS fragmentation pattern matched that of PC 
(16:0/16:1) (Supplementary Fig. 1F).
We also picked up several insignificant lipids identified by the global metabolomic analysis with LC–MS 
and summarised them in the Supplemental Table 3. The VIP scores of these candidate lipids are low, and there 
is almost no difference in the average signal intensity between normal lung and lung adenocarcinoma tissues. 
However, we did not use standard compounds to identify these insignificant lipids.
There were significant differences between the adenocarcinoma and normal lung specimens in the relative 
abundances of PC (16:0/16:0) and SM (42:2), especially in the latter (P < 0.0001). The mean abundances of both 
lipids were higher in the normal lung specimens than the adenocarcinoma specimens. In contrast, there were no 
significant differences between the 2 groups in the mean abundances of PC (16:0/18:1) (P = 0.2879) and PC (36:4) 
(P = 0.2454) (Fig. 2A–D). As shown in Fig. 2E,F, the ratios of PC (16:0/16:1)/PC (16:0/16:0), PC (16:0/18:1)/PC 
(16:0/16:0), and PC (16:0/18:1)/PC (16:0/18:0) were significantly higher in the adenocarcinoma specimens than 
the normal lung specimens (P = 0.02221, P = 0.0004, and P = 0.0215, respectively).
MALDI-IMs analysis results. The intra-lung distribution of the various lipid species and the ratios of their 
abundances were examined using MALDI-IMS. The typical mass spectra of samples from adenocarcinoma and 
normal lung specimens are presented in Fig. 3. The samples shown in Figs 3 and 4 were collected from Patient 14 
(shown in Table 1).
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Figure 4A shows the different distribution of ions between the tumour region and surrounding normal lung 
parenchyma as revealed by haematoxylin and eosin (H&E) staining. Figure 4B shows an electron microscope 
image of the same area. We present MALDI-IMS images from adjacent or near-adjacent sections of ions at m/z 
734.57 (PC [16:0/16:0]) in Fig. 4C and at m/z 760.58 (PC [16:0/18:1]) in Fig. 4D. Supplementary Fig. 2 shows 
MALDI-IMS images of ions at m/z 732.55 (PC [16:0/16:1]), m/z 762.60 (PC [16:0/18:0]), m/z 782.57 (PC [36:4]), 
and m/z 813.68 (SM [42:2]).
As shown in Fig. 5, the intensity ratios of PC (16:0/16:1)/PC (16:0/16:0), PC (16:0/18:1)/PC (16:0/16:0), and 
PC (16:0/18:1)/PC (16:0/18:0) were significantly higher (P < 0.0001) in the adenocarcinoma specimens than the 
normal lung specimens, which was consistent with the results from the LC-MS analysis.
The intensity ratio of PC (16:0/18:1)/PC (16:0/18:0) was significantly lower in solid predominant tumour 
specimens than the other subtypes (n = 8 vs 17; P = 0.0028) (Fig. 6).
Discussion
Cancer-associated metabolic processes have been the subject of numerous studies since it was discovered that 
cancer cells demonstrate an upregulation of glycolysis and lactate production19. Many types of cancer show 
increased glucose uptake and enhanced glycolytic rates, which suggests that the rapid growth of tumour cells 
contributes to metabolic alterations. In lung cancer, the activation of lipid metabolism has been suggested to be a 
hallmark of carcinogenesis10,12,14,20.
First, we performed global metabolome analysis (LC–MS) using three cases and three controls (the total sam-
ple size was 6) and identified the molecules with m/z of 734.57, 813.68, 760.58 and 782.56 to be significant candi-
dates. The molecule with m/z of 760.58 was identified to be a protonated ion of PC (16:0/18:1). Because previous 
studies have reported increases in PC (16:0/18:1) in lung cancer cells10,12,14, we closely observed PC (16:0/18:1). 
From the standard deviation and mean difference of m/z760.58 using three cases and three controls (the total 
sample size was 6), we confirmed that the total sample size we have used (N = 12, six cases and six controls) was 
acceptable at least for the comparison of the candidate molecules.
In this study, we conducted an in-depth comparative investigation of the lipid profiles of lung adenocarcinoma 
and normal lung specimens using LC-MS to shed light on the metabolic processes in the lung cancer microenvi-
ronment. In the S-plot shown in Fig. 1, PC (16:0/16:0) and SM (42:2) were found to be abundant in normal lung 
specimens, whereas PC (16:0/18:1) and PC (36:4) were more abundant in lung adenocarcinoma specimens.







1a 71 MP t1 n0 IA IA3 22
2a 70 Pap t1 n0 IA IA3 23
3a 70 Solid t1 n0 IA IA3 29
4a 42 Acinar t1 n0 IA IA3 27
5a 76 Mucinous t2 n0 IB IIA 45
6a 76 Pap t2 n0 IB IB 39
7 66 Acinar t2 n0 IB IB 34
8 46 Acinar t2 n2 IIIA IIIA 38
9 73 Lep t1 n0 IA IA2 18
10 66 Lep t1 n0 IA IA3 22
11 72 MP t1 n0 IA IA3 24
12 82 Mucinous t1 n0 IA IA2 12
13 65 Mucinous t4 n0 IIIB IIIA 80
14b 64 Pap t1 n0 IA IA3 26
15 64 Pap t1 n0 IA IA3 25
16 54 Pap t1 n0 IA IA2 17
17 72 Pap t1 n0 IA IA2 20
18 60 Pap t1 n1 IIA IA3 27
19 70 Solid t1 n0 IA IA2 15
20 62 Solid t1 n0 IA IA2 20
21 75 Solid t1 n0 IA IA3 21
22 77 Solid t2 n0 IB IIA 43
23 58 Solid t2 n0 IB IIA 40
24 74 Solid t1 n1 IIA IIB 23
25 72 Solid t2 n1 IIB IIB 38
Table 1. Clinicopathological features of the patients. aDenotes patients who underwent both liquid 
chromatography–mass spectrometry and imaging mass spectrometry analyses. bSamples from Patient 14 were 
used in the histological analysis, electron microscope imaging, and liquid chromatography–mass spectrometry 
and imaging mass spectrometry analyses shown in Figs 3 and 4. MP = Micropapillary. Pap = Papillary. 
Lep = Lepidic. UICC = Union for International Cancer Control.
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We also found that PC (16:0/16:0) and SM (42:2) were significantly less abundant in all lung adenocarcinoma 
specimens than in normal lung tissue (Fig. 2A,D).
Pulmonary surfactant, a complex of lipids and proteins secreted by type II alveolar cells, reduces the surface 
tension at the air-liquid interface17,18,21. This surfactant consists of PC, SM, and various surfactant proteins (e.g., 
SP-A, SP-B, SP-C, and SP-D). PC (16:0/16:0), or dipalmitoylphosphatidylcholine, is a main component of pulmo-
nary surfactant17,18. We posit that a reduction in the number of normal type II alveolar cells in the tumour region 
may have contributed to the observed reduction of PC (16:0/16:0) in the adenocarcinoma specimens.
Our experiments detected a prominent difference in the abundance of SM (42:2) between adenocarcinoma 
and normal lung specimens (P < 0.0001). This suggests the presence of a specialized metabolic pathway for SM 
(42:2) in lung cancer cells. SM, which is the major sphingolipid in mammalian cells and represents one of the 
main lipid components of pulmonary surfactant, has also been reported to decrease in other tumour cells22. SM 
also has shown an anti-cancer effect in colon cancer23. Based on our findings, we believe that decreases in the 
abundance of PC (16:0/16:0) and SM (42:2) may have useful applications in the auxiliary diagnosis of adenocarci-
noma. These 2 lipids may therefore play important roles as key lipids in cancer metabolism. On the other hand, we 
found no significant differences in the mean abundance of PC (16:0/18:1) (P = 0.2879) and PC (36:4) (P = 0.2454) 
between adenocarcinoma and normal lung specimens (Fig. 2B,C). In contrast, previous studies have reported 
increases in PC (16:0/18:1) in lung cancer cells10,12,14. We were unable to identify the reasons for this discrepancy, 
and further analyses are needed to determine if these 2 lipids have potential applications in cancer diagnoses.
The levels of monounsaturated fatty acids and monounsaturated PCs have been reported to be significantly 
higher than those of saturated and polyunsaturated PCs in the cancer microenvironment8–11. Therefore, our study 
focused on the ratios of PC (16:0/16:1)/PC (16:0/16:0), PC (16:0/18:1)/PC (16:0/16:0), and PC (16:0/18:1)/PC 





Table 2. Variable importance in projection (VIP) score of the OPLS-DA in the top four ions VIP, variable 
importance in projection.
Figure 1. (A) S-plot of the orthogonal projection to latent structures discriminant analysis of adenocarcinoma 
(ADC) and normal lung (NL) specimens. The X-axis and Y-axis show the degree of quantitative contributions 
and qualitative contributions, respectively. Positive values are more representative of ADC specimens and 
negative values are more representative of NL specimens. (B) Score-plot of the orthogonal projection to latent 
structures discriminant analysis of adenocarcinoma (ADC) and normal lung (NL) specimens.
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(16:0/18:0). Our experiments showed that these ratios were significantly higher in the lung adenocarcinoma 
specimens than the normal lung specimens. The detection of increases in these ratios may therefore have useful 
applications in the auxiliary diagnosis of cancer.
Figure 3. Typical mass spectra of samples from adenocarcinoma (A) and normal lung specimens (B). The data 
shown in this figure were obtained from Patient 14 in Table 1.
Figure 2. Box plots showing the relative abundance of each lipid (A–D) and the ratios of monounsaturated 
phosphatidylcholine (PC) to saturated PC (E–G) in adenocarcinoma (ADC) and normal lung (NL) specimens 
from 6 patients through liquid chromatography–mass spectrometry analysis. P values were calculated using 
Student’s t-test.
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MALDI-IMS is an MS technique that facilitates the acquisition of mass spectra directly from specimens 
and constructs density maps of the detected ions. While conventional MS analyses require lipid extraction, 
MALDI-IMS does not involve the destruction of histological structures in specimens. In addition, analysts are 
able to compare the MALDI-IMS images with corresponding optical images24,25. MALDI-IMS is therefore com-
monly used to investigate the localization of lipids in cancer specimens. In this study, we considered MALDI-IMS 
to be the best tool to examine lipid distribution in the adenocarcinoma specimens, which demonstrate various 
pathological characteristics. Similar to the results of the LC-MS analysis, the MALDI-IMS analysis found sig-
nificantly higher signal intensity ratios of PC (16:0/18:1)/PC (16:0/18:0), PC (16:0/16:1)/PC (16:0/16:0), and PC 
(16:0/18:1)/PC (16:0/16:0) in the lung adenocarcinoma specimens than the normal lung specimens. The results 
from the 2 analytical approaches indicated that lung adenocarcinoma specimens have a higher expression of 
monounsaturated PCs than normal lung specimens. In this way, the LC-MS results were revaluated and con-
firmed using the MALDI-IMS analysis, which was supplemented with information on intra-lung localization of 
each lipid.
Although it is said our MALDI-IMS instrument has the ability to perform MS/MS analysis, we could not get 
MS/MS information of MALDI-IMS in this study. Interfering noises were mixed in the background during MS/
MS analysis, and it was extremely difficult to identify clear MS/MS fragmentation patterns. We could not clarify 
the reason why MS/MS analysis using MALDI-IMS did not work. It might be controversial whether the results of 
the LC–MS/MS and MALDI-IMS analyses are in perfect correspondence. However, we believe that their corre-
spondence is highly likely because of the following: (1) We used the same specimens. (2) The observed accurate 
masses were identical for corresponding molecules. (3) The characteristics and abundance of the corresponding 
molecules are very similar. They all were quite abundant in lung specimens and very easily and strongly ionised.
Analysis of the adenocarcinoma subtypes revealed that the PC (16:0/18:1)/PC (16:0/18:0) ratio was signifi-
cantly lower in solid type tumours than in the other subtypes (P = 0.0028). We suspect that this difference is influ-
enced by enzymes that play an important role in PC synthesis. PCs are synthesized via de novo and remodelling 
pathways11,26. Figure 7 shows a schematic diagram of PC development. In the remodelling pathway, monoun-
saturated fatty acids (palmitoleic acid [16:1] and oleic acid [18:1]) are endogenously produced from their corre-
sponding saturated fatty acids (palmitic acid [16:0] and stearic acid [18:0]) through the action of stearoyl-CoA 
desaturase-1 (SCD-1), and subsequently converted into monounsaturated PC. SCD-1 is thought to play an impor-
tant role in cancer progression27. In addition, lyso-PC acyltransferases (LPCATs) and elongation of very long fatty 
Figure 4. Histological image with haematoxylin and eosin staining (A), electron microscope image (B), and 
matrix-assisted laser desorption/ionization imaging mass spectrometry images (C,D) of adjacent or near-
adjacent sections from a single patient (Patient 14 in Table 1). (C) shows an ion image of phosphatidylcholine 
(PC) (16:0/16:0), and Fig. 4d shows an ion image of PC (16:0/18:1). Haematoxylin and eosin staining indicated 
papillary adenocarcinoma in the left side of the histological image (A), and the right side was identified 
as normal lung tissue. PC (16:0/16:0), which was the most abundant lipid in the normal lung region, was 
concentrated along the alveolar wall (C). In contrast, PC (16:0/18:1), which was the most abundant lipid in the 
tumour region, was concentrated among the tumour cells (D). Bar: 200 μm. The boundary between the tumour 
tissue and the normal tissue is pointed by yellow arrow head.
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acids (ELOVLs) have also been reported to be important components of PC metabolism11,16,26,28. LPCATs, which 
catalyse the reacylation of phospholipids, are particularly important in PC synthesis. ELOVL6 is a rate-limiting 
enzyme that catalyses the elongation reaction of palmitic acid [16:0] to stearic acid [18:0]16. Although it is difficult 
to determine the reason for the different PC (16:0/18:1)/PC (16:0/18:0) ratio between solid tumours and the other 
subtypes, we posit that the difference may be driven by the aforementioned enzymes.
Limitations. First, there was a relatively small number of samples in this study. Specifically, the sample size 
for each adenocarcinoma subtype was small, and there was a bias in the number of samples in each subtype group. 
We also have the advanced cases in our sample, although most samples were from pathological Stage I. There may 
be also some individual differences of lipids metabolism among different patients. We could not clearly identify 
the reliability using multivariate analysis, and we did not practicality validate the cross-validation or data training 
model in this small number of groups. Therefore, future studies should be conducted using larger sample sizes for 
each subtype and pathological Stage.
Second, several different key enzymes are involved in the metabolic pathways of phospholipids. As this study 
focused on comparing the abundance of metabolic products between normal lung and lung adenocarcinoma 
Figure 5. Box plots of the ratios of monounsaturated phosphatidylcholine (PC) to saturated PC (A–C) between 
adenocarcinoma (ADC) and normal lung (NL) specimens. P values were calculated using Student’s t-test.
Figure 6. Box plot of the ratio of phosphatidylcholine (PC) (16:0/18:1) to PC (16:0/18:0) between solid 
adenocarcinoma and other subtypes. The P value was calculated using Student’s t-test.
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specimens, we remain uncertain as to which enzymes are actually active in these metabolic pathways in ade-
nocarcinoma tissue. This mechanism should be further examined using additional experiments (such as 
immune-histochemical validation) to elucidate the roles of enzymes such as SCD-I, LPCATs, and ELOVL6.
Finally, it is quite difficult to precisely discriminate the positions of double bonds in acyl groups by MS/MS 
fragmentation using the LC–MS system because of the similar fragmentation patterns and close retention times. 
The names of the lipids in our identification results lack the position information of the double bonds. The posi-
tions of acyl-sn would play an important role in cancer phenotype, and it would be the subject of a future study.
Conclusion
The lung adenocarcinoma microenvironment is characterized by significantly higher ratios of monounsatu-
rated PCs to saturated PCs, and the solid tumour subtype possibly had a lower ratio than the other adenocarci-
noma subtypes. Despite the above limitations, we believe that our study will be important in the field of cancer 
metabolism.
Materials and Methods
Clinical specimens. Samples of lung adenocarcinoma and normal lung tissue were obtained from patients 
who underwent lung cancer surgery in the Department of Thoracic Surgery, Kyoto University Hospital (Kyoto, 
Japan) between January 2013 and December 2014. All samples were collected in accordance with ethical guide-
lines, and all patients were approached based on approved ethical guidelines. Written informed consent was 
obtained from all patients prior to inclusion in the study (Authorization Number: R0097). A total of 25 patients 
who underwent pulmonary resection for lung adenocarcinoma with curative intent were included in analysis. 
Twenty-five patients were included to ensure that each invasive adenocarcinoma subtype (lepidic, acinar, papil-
lary, micropapillary, solid, and mucinous) was represented for the pathological diagnosis.
Adenocarcinoma and normal lung specimens (each several square millimetres in size) were harvested from 
these patients and flash frozen in liquid nitrogen. The specimens were stored at −80 °C until used in the experi-
ments. Normal lung specimens were harvested from parts of the lung distant from the tumour within the same 
lobe. All H&E-stained slides were evaluated by a pathologist and a thoracic surgeon to determine the subtype of 
adenocarcinoma. These slides were used as a guide for MALDI-IMS analysis.
LC-Ms analysis. The frozen specimens were excised using a disposable scalpel and weighed after freezing. 
Total lipids were extracted using a commercial lipid extraction kit (BioVision Inc, Milpitas, CA, USA). The volume 
of extraction solution was determined according to the measured weight of each specimen. The volume-matched 
lipid extracts for each specimen were aliquoted and dried under nitrogen before being reconstituted in a mixture 
of 50% isopropanol/25% acetonitrile/25% water. The reconstituted samples were separated using an ultra-high 
performance liquid chromatography H-class system (Waters, Milford, MA, USA) with a binary gradient pump. 
The gradient program was as follows: 40% to 43% B in 2 min (Curve 6), 43% to 50% B in 0.1 min (Curve 1), 50% 
to 54% B in 9.9 min (Curve 6), 54% to 70% B in 0.1 min (Curve 1), 70% to 99% B in 5.9 min (Curve 6), 99% to 40% 
B in 0.1 min (Curve 6), and 40% B for 1.9 min. Mixtures of 0.1% formic acid/10 mM ammonium formate/60% 
acetonitrile and 0.1% formic acid/10 mM ammonium formate/10% acetonitrile/90% isopropanol were used as 
mobile phases A and B, respectively. The flow rate was set to 0.4 mL/min. The eluates from ultra-high perfor-
mance liquid chromatography were infused online to a Xevo G2-S Q-Tof mass spectrometer equipped with an 
ESI ion source (Waters). MS was performed in the electrospray ionization positive ion mode. For global lipid pro-
filing, datasets were obtained using MSE Technology (Waters), in which the MS and MS/MS spectra were acquired 
globally in a single run. Collision-induced dissociation was utilised for the authentic MS/MS spectral analyses. 
Datasets were acquired with precursor m/z values and fixed collision energies optimal for each compound. The 
optimal collision energies for each compound were determined through the stepwise screening of the voltages 
(from 10 to 200 V). The datasets obtained from the global lipid profiling (Six cases; pairs of 6 adenocarcinoma 
specimens and 6 normal lung specimens) were exported to Progenesis QI software (Nonlinear Dynamics, New 
Castle upon Tyne, UK) for analysis. Alignments, peak findings, relative abundance calculations, and database 
Figure 7. Presumed schematic diagram of phosphatidylcholine (PC) development. Monounsaturated fatty 
acids are endogenously produced from the corresponding saturated fatty acids through the action of stearoyl-
CoA desaturase-1 (SCD-1). Lyso-PC acyltransferase (LPCAT) may catalyse the synthesis of PC in pulmonary 
surfactant and play a critical role in respiratory physiology. Elongation of very long fatty acids 6 (ELOVL6) is a 
rate-limiting enzyme that catalyses the elongation reaction of C16:0 to C18:0.
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searches of LIPID MAPS [https://www.lipidmaps.org/] and the Human Metabolome Database [http://www.
hmdb.ca/] were performed using Progenesis QI. The peak areas for each compound were normalized to total 
compound intensity and examined as relative abundances. The normalized relative abundances of all compounds 
were exported to EZinfo (Umetrics, Umea, Sweden). OPLS-DA was performed using EZinfo, and the obtained 
result was converted to the S-plot format. The reliability of compound identification by Progenesis QI was revalu-
ated using the authentic MS/MS spectral analyses in which standard compounds (if commercially available) were 
measured by the same LC-MS system with appropriate modifications to the MS settings. Lipid standards (PC 
[16:0/16:0], PC [16:0/18:1], and PC [16:0/18:0]) were purchased from Avanti Polar Lipids (Alabaster, AL, USA).
MALDI-IMs analysis. The frozen specimens were sectioned on a cryostat (CM1850; Leica, Wetzler, 
Germany) at −20 °C. Cryosections of 8-μm thickness were mounted onto indium–tin oxide slides, and every 
other section was mounted onto common glass slides for H&E staining. The slides for adenocarcinoma speci-
mens and normal lung specimens were prepared separately. This process was entrusted to the Kyoto Nutrition 
Pathology Laboratory. Each section was coated with 9-aminoacridine hemihydrate (Acros Organics, Geel, 
Belgium), which served as the matrix for MALDI-IMS. The slides were anchored in a vacuum deposition cham-
ber (SVC-700TM/700-2; Sanyu Electron, Tokyo, Japan) and mechanically coated with 9-aminoacridine hemihy-
drate evaporated at −20 °C. The time required for this vapor deposition process was 8 min.
High-resolution MALDI-IMS analysis was performed on a high-resolution microscopic imaging mass spec-
trometer (RK27-4050C; Shimadzu, Kyoto, Japan; the prototype model of IMScope) equipped with a 355-nm 
Nd:YAG laser. MS data were acquired in positive ion mode in the 500.0–1200.0 m/z range using an external 
calibration method. Each region of interest was determined from the microscopic view of the slides and referring 
to the adjacent H&E-stained sections. We selected regions of interest that were mainly occupied by one subtype 
(>50%); mass spectra were obtained at a spatial resolution of 10 μm.
The spectra and mean signal intensities of the regions of interest were analysed, and the MS data were nor-
malized to the total ion current to eliminate variations in ionization efficiency using the Imaging MS Solution™ 
program (Shimadzu).
statistical analysis. The difference in signal intensities or signal intensity ratios were compared using 
Student’s t-test. Statistical analyses were performed using JMP version 12.0 (SAS, Cary, NC, USA), and P values 
below 0.05 were considered statistically significant.
ethical statement. All study protocols were approved by the Ethics Committee for Clinical Research, Kyoto 
University Hospital (Approval number: R369).
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